Improving Sleep After TKA Using Mirtazapine and Quetiapine

Sponsor
St. Anna Ziekenhuis, Geldrop, Netherlands (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04728581
Collaborator
(none)
165
2
3
20
82.5
4.1

Study Details

Study Description

Brief Summary

Use of mirtazapine and quetiapine for improvement of sleep quality after TKA

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Background After knee replacement surgery there is a loss of quantity and quality of sleep. Loss of sleep is associated with increased pain perception. Subsequently, patients use more analgesic medication and it takes them longer to fully recover from surgery. Low doses of the tetracyclic antidepressant mirtazapine and the neuroleptic quetiapine are nowadays off-label prescribed for insomnia and improve length and quality of deep sleep phases. Quetiapine and mirtazapine could improve sleep after knee replacement surgery and improve patient recovery. This placebo-controlled, randomized, double-blind study investigates the effect of quetiapine and mirtazapine on functional recovery after total knee arthroplasty.

Methods This is a prospective, single center, double-blinded randomized controlled trial. 165 patients with knee osteoarthritis scheduled for total knee arthroplasty will be randomly allocated to a low-dose quetiapine (LDQ), a low-dose mirtazapine (LDM) group or a placebo group. Outcomes will be evaluated at baseline, 2, 4, 6 and 12 weeks after surgery. Functional outcome after total knee arthroplasty is measured using a patient related outcome measure through the Oxford Knee Score (OKS). In order to measure postoperative sleep quality, patients will be monitored using the Leeds Sleep evaluation questionnaire (LSEQ). Furthermore, pain is registered using a visual analogue scale (VAS), weekly opioid use is monitored, and general health status is reported through the EQ-5D. Analyses will be conducted on an intention-to-treat basis using logistic and linear mixed regression models. This trial complies with the SPIRIT guidelines for randomized controlled trials.

Discussion This study will provide clinicians with evidence whether quetiapine contributes to rehabilitation of patients undergoing fast-track knee replacement surgery.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
165 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Placebo controlled trial
Primary Purpose:
Treatment
Official Title:
Mirtazapine and Quetiapine as Treatment for Postoperative Sleep Disturbance After Fast-track Knee Replacement
Anticipated Study Start Date :
May 1, 2021
Anticipated Primary Completion Date :
May 1, 2022
Anticipated Study Completion Date :
Jan 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Placebo

use of placebo during first 2 weeks after TKA surgery

Drug: Placebo
a gelatinous capsule without an active ingredient

Experimental: Low dose Mirtazapine

Use of Mirtazapine 3.75mg before lights-out, allowed to increase medication to 7.5mg

Drug: Mirtazapine
Use of 3.75mg mirtazapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 7.5mg mirtazapine.

Experimental: Low dose Quetiapine

use of Quetiapine 3.125mg before lights-out, allowed to increase medication to 6.25mg

Drug: Quetiapine
Use of 3.125mg quetiapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 6.25mg mirtazapine.

Outcome Measures

Primary Outcome Measures

  1. Oxford Knee Score (OKS) [6 weeks after surgery]

    Validated functional knee score after TKA, minimum score 12 (best outcome), maximum score 60 (worst outcome)

Secondary Outcome Measures

  1. Leeds Sleep Evaluation questionnaire (LSEQ) [1 week before surgery; first day postoperative; 2; 4; 6; 12 weeks after surgery]

    Validated sleep score in 3 dimensions of sleep

  2. Visual Analogue Scale (VAS) for fatigue [1 week before surgery; first day postoperative; 2; 4; 6; 12 weeks after surgery]

    Visual analogue reporting of fatigue after sleep, indicated on a 0 (best outcome) to 100 (worst outcome) mm line

  3. Visual Analogue Scale (VAS) for sleep quality [1 week before surgery; first day postoperative; 2; 4; 6; 12 weeks after surgery]

    Visual analogue reporting of quality sleep, indicated on a 0 (worst outcome) to 100 (best outcome) mm line

  4. Visual Analogue Scale (VAS) for pain in rest [1 week before surgery; first day postoperative; 2; 4; 6; 12 weeks after surgery]

    Visual analogue reporting of knee pain while resting, indicated on a 0 (best outcome) to 100 (worst outcome) mm line

  5. Visual Analogue Scale (VAS) for pain during activity [1 week before surgery; first day postoperative; 2; 4; 6; 12 weeks after surgery]

    Visual analogue reporting of knee pain during exercises, indicated on a 0 (best outcome) to 100 (worst outcome) mm line

  6. EuroQol (EQ) 5D [1 week before surgery; first day postoperative; 2; 4; 6; 12 weeks after surgery]

    General well being score, full health represented by 11111 score (overall score for the Netherlands of 1,000), worst health represented by 55555 score (overal score for the Netherlands of -0,329)

  7. Morphine use [1 week before surgery; first day postoperative; 2; 4; 6; 12 weeks after surgery]

    Total amount (mg) morphine use after surgery is documented

  8. Oxford knee score [1 week before surgery; first day postoperative; 2; 4; 12 weeks after surgery]

    Validated functional knee score after TKA, minimum score 12 (best outcome), maximum score 60 (worst outcome)

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Indication for TKA
Exclusion Criteria:
  • use of benzodiazepines

  • use of anti-depressants

  • use of oxycodone

  • patients diagnosed with obstructive sleep apnea syndrome, severe respiratory insufficiency, or myasthenia

  • a known hypersensitivity to mirtazapine, quetiapine and/or related to the gelatinous (placebo) capsule

  • insufficient understanding of the Dutch language.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Knowledge Center for Orthopedic Surgery, St. Anna hospital Geldrop Netherlands
2 St. Anna hospital Geldrop Netherlands

Sponsors and Collaborators

  • St. Anna Ziekenhuis, Geldrop, Netherlands

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Walter van der Weegen, PhD, St. Anna Ziekenhuis, Geldrop, Netherlands
ClinicalTrials.gov Identifier:
NCT04728581
Other Study ID Numbers:
  • W021-001
First Posted:
Jan 28, 2021
Last Update Posted:
Jan 28, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 28, 2021